Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting

Ruben Niesvizky • 25 Oct 2021
LLM 2021
Multiple Myeloma Antibodies CAR-T

Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, discusses future strategies for consolidation therapy in multiple myeloma. Prof. Niesvizky explains that novel therapies including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy that have shown high efficacy in relapsed/refractory disease could potentially be used as an alternative to stem cell transplantation in the consolidation setting. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Ruben Niesvizky

2:51
Key myeloma discussion topics at LLM 2021
Ruben Niesvizky • 25 Oct 2021
1:41
Innovative treatment strategies for multiple myeloma
Ruben Niesvizky • 25 Oct 2021
1:22
Using molecular techniques to define risk in patients with myeloma
Ruben Niesvizky • 25 Oct 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals